U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 1 of 1 results

Status:
US Approved Rx (2019)
First approved in 2002

Class (Stereo):
CHEMICAL (EPIMERIC)



Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both b...